Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection

Do Young Kim, Hong Jeoung Kim, Chun Kyon Lee, Jeong Hun Suh, Dong Hwan Kim, Yong Suk Cho, Sun Young Won, Byung Kyu Park, In Suh Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is known to be effective for lamivudine-resistant hepatitis B virus (HBV) mutants as well as wild-type HBV. The aim of this study is to assess the efficacy of ADV against lamivudine-resistant genotype C HBV mutants. Methods: Thirty-five patients with breakthrough hepatitis due to lamivudine-resistant HBV received ADV 10mg daily with discontinuation of lamivudine. Quantitative HBV DNA, HBeAg, liver function test including alanine aminotransferase (ALT) was checked every 4-12 weeks to evaluate the efficacy of ADV. Results: ADV was administered for a median of 48 weeks (range: 24-120 weeks). The rate of serum HBV DNA loss was 68.6%, 80.0%, 84.0%, and 88.2% at weeks 12, 24, 36, and 48, respectively. The rate of serum HBeAg seroconversion was 8.3% and 14.3% at weeks 24 and 48, respectively. The rate of serum ALT normalization at week 48 was 70.6%. Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9pg/ml in 88.9% of patients, who were treated for a median of 40 weeks. Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal. Conclusions: Administration of ADV is an effective option for the treatment of patients with lamivudine-resistant genotype C HBV infection.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalLiver International
Volume27
Issue number1
DOIs
Publication statusPublished - 2007 Feb 1

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection'. Together they form a unique fingerprint.

  • Cite this

    Kim, D. Y., Kim, H. J., Lee, C. K., Suh, J. H., Kim, D. H., Cho, Y. S., Won, S. Y., Park, B. K., & Park, I. S. (2007). Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. Liver International, 27(1), 47-53. https://doi.org/10.1111/j.1478-3231.2006.01407.x